Preclinical work has shown that IL-6/STAT3 signaling takes control of a subset of shared IL-6/ER-enhancers to both drive BC invasion and render the BC resistant to ET, and that this process can be inhibited through blockade of IL-6/STAT3 with ruxolitinib, an oral JAK1/2 inhibitor11. Here, IL6 is linked to breast cancer.